Resof-l

Treatment of Chronic hepatitis C virus (HCV) infection

The human body reacts differently to Resof-L Tablet. Response or undesired symptoms vary from individual to individual. Usually, they disappear with time as the body adjusts to the medicine; these side effects don't need special medical attention. Whereas if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately. Some of the common side effects of Resof-L Tablet  are mentioned below:

Headache
Fever
Chills
Nausea
Insomnia (difficulty in sleeping)
Tiredness
Loss of appetite
Fatigue Anemia (low number of red blood cells)
Skin rash

Take the dose of Resof-L Tablet as per your healthcare provider’s prescription. Do not stop taking the medicine suddenly, unless your doctor tells you. This medicine is given under the strict supervision of a doctor. Do not self-administer. Overdose is a very unusual state for this medicine because it is given under the supervision of a healthcare provider. Resof-L Tablet can be taken without food or with food. The doctor will provide emergency medical treatment. You should not break, crush, or chew the medicine; it should be swallowed as a whole. It is advised to eat a healthy diet and drink plenty of fluids to overcome and prevent the side effects that have occurred after taking ​Resof-L Tablet.

Resof-L Tablet is an antiviral medicine made up of Sofosbuvir and Ledipasvir. Both ingredients present in the medicine prevent the virus from multiplying. Thus, the viral count in the blood gets lowered, and the infection can be eliminated from the body. This medication is suitable for use in both adults and children aged three years and above. Resof-L Tablet inhibits an important Nonstructural protein 5A (NS5A) and viral phosphoprotein, which are involved in replication of the virus, assembly, secretion, and RNA viral production.

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

Abergel A, Asselah T, Metivier S, Kersey K, Jiang D, Mo H, Pang PS, Samuel D, Loustaud-Ratti V. (2023). Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. Lancet Infect Dis. 16(4):459-64.

Duc N. T, Vittorio F, Alexander Z, Venkat R. G, Akihiro H, Mingjun H, Jason A. W. (2025). The Discovery and Chemical Development of Odalasvir, a Potent and Selective HCV NS5A Inhibitor, Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 5, 1-58.

Lele Z, Matthew H, Prahalad G, Mahan G, Steven K, Haiting C, Paul K, Eleanor B, M. Azim A, Katrina L, Genetically distinct within-host subpopulations of hepatitis C virus persist after Direct-Acting Antiviral treatment failure, PLOS Pathogens, 21, 4, (e1012959).

Nambaru Vidya Sagar, Anamika Goyal, Abhishek Raj, Subhash Chandra, Upendra Nath Gupta, Prabhat Agrawal, Rajat Gupta, Rahul Agrahari. (2024). SVR timelines in hepatitis irrespective of viral genotype: An Indian perspective, Journal of Family Medicine and Primary Care, 14, 4, 1425-1430.

Preferred Therapy for Specific Viral Pathogens, Nelson’s Pediatric Antimicrobial Therapy, (2025).

Thomas R. O, David J. W, Varun S, Kerry G.M., Sabrina C, Francine S.B., Ludmila P. O, Ruth M. P, Jennifer B. L. (2024). IFNL4 genotype and other personal characteristics to predict response to 8-week sofosbuvir-based treatment for chronic hepatitis C, Journal of Infection, 89, 5, (106258).

Yong P, Sitthichai K, Nungruthai S, Pornjarim N, Ritthideach Y, Wijittra P, Napaporn P, Chatree J. (2025). Microelimination of Hepatitis C in Thailand, Phetchabun Model: Progress, Challenges, and Future Directions, Journal of Clinical Medicine, 14, 11, 3946.